A detailed history of Alliancebernstein L.P. transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 40,020 shares of KALV stock, worth $406,203. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40,020
Previous 42,450 5.72%
Holding current value
$406,203
Previous $500,000 7.4%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$9.46 - $15.39 $22,987 - $37,397
-2,430 Reduced 5.72%
40,020 $463,000
Q2 2024

Aug 14, 2024

BUY
$10.35 - $12.49 $128,754 - $155,375
12,440 Added 41.45%
42,450 $500,000
Q4 2023

Feb 14, 2024

SELL
$7.58 - $12.25 $18,192 - $29,400
-2,400 Reduced 7.41%
30,010 $367,000
Q2 2023

Aug 15, 2023

BUY
$7.73 - $10.57 $51,868 - $70,924
6,710 Added 26.11%
32,410 $291,000
Q4 2022

Feb 14, 2023

BUY
$4.2 - $14.24 $36,271 - $122,976
8,636 Added 50.61%
25,700 $173,000
Q3 2022

Nov 15, 2022

BUY
$9.85 - $16.83 $19,345 - $33,054
1,964 Added 13.01%
17,064 $248,000
Q2 2022

Aug 15, 2022

BUY
$8.16 - $15.1 $38,352 - $70,970
4,700 Added 45.19%
15,100 $149,000
Q1 2022

May 13, 2022

SELL
$11.2 - $16.97 $20,160 - $30,545
-1,800 Reduced 14.75%
10,400 $153,000
Q2 2021

Jul 30, 2021

BUY
$23.12 - $29.91 $282,064 - $364,902
12,200 New
12,200 $292,000
Q1 2021

May 06, 2021

SELL
$14.69 - $42.57 $276,172 - $800,316
-18,800 Closed
0 $0
Q4 2020

Feb 08, 2021

SELL
$12.88 - $19.47 $11,592 - $17,523
-900 Reduced 4.57%
18,800 $357,000
Q2 2020

Aug 13, 2020

BUY
$6.75 - $12.89 $49,950 - $95,386
7,400 Added 60.16%
19,700 $238,000
Q1 2020

May 14, 2020

BUY
$5.8 - $18.56 $12,760 - $40,832
2,200 Added 21.78%
12,300 $94,000
Q3 2019

Nov 14, 2019

BUY
$11.6 - $21.67 $117,160 - $218,867
10,100 New
10,100 $117,000

Others Institutions Holding KALV

About KalVista Pharmaceuticals, Inc.


  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $250M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.